SHANGHAI, March 22, 2026 /PRNewswire/ — On the occasion of World Water Day, WuXi Biologics reaffirms its commitment to sustainability through responsible operations and efficient, circular water‑use practices that reduce environmental impact.

WuXi Biologics has been named to the CDP Water Security “A List” for three consecutive years, underscoring an industry-leading performance in environmental stewardship and transparency. This achievement reflects the company’s long-standing dedication to sustainable water management, including its diligent efforts to meet water targets, fulfill clients’ sustainability expectations, and continually enhance water management practices.

Significant Progress in Systematic Water Management 

WuXi Biologics actively supports the United Nations Sustainable Development Goal regarding clean water and sanitation (SDG 6), and has established a comprehensive water management framework with clear targets and ongoing progress tracking. With 2019 as the base year, the company aimed to reduce water consumption intensity by 30% by 2025, and, at the conclusion of 2025, had fully achieved this ambitious goal, demonstrating the company’s unflagging commitment to excellence in water stewardship, and the success of its endeavors to improve water efficiency and minimize its environmental footprint.

Roll Out of WES Across Global Operations

To promote and support site-specific water stewardship and management across the company, WuXi Biologics launched a Water Excellence Stewardship (WES) program in 2024 covering such material topics as water governance, water balance, water quality, and safe water/environmental and personal hygiene (WASH). Through WES, each site can assess its own sustainable water management performance, identify improvement opportunities, and ensure alignment with international best practices. By the end of 2025, the WES program had been rolled out at 10 of the company’s global sites.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “Natural resources are fundamental to the human well-being, and are indispensable in the the research, development and production of biologics. WuXi Biologics is committed to protecting the environment and pursuing sustainability by operating responsibly, while advancing exemplary water stewardship, and promoting universal access to water and sanitation. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide to fulfill ESG commitments, and jointly work with all stakeholders to promote responsible practices throughout the entire value chain.”

As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. In addition to being named to the CDP “A List” for Water Security, the company was named to the CDP “A List” for Climate Change and rated “A” in the CDP Supplier Engagement Assessment; granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Best-in-Class Indices; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng Corporate Sustainability Benchmark Index; and rated as Prime by ISS ESG Corporate Rating.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

ESG
esg@wuxibiologics.com

Media
PR@wuxibiologics.com

SEOUL, South Korea, March 22, 2026 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, today announced that it is beginning the world’s first-ever mass production of an LCD panel for laptops equipped with its Oxide 1Hz technology.

The panel’s core feature is its ability to intelligently detect the usage environment. It automatically switches the refresh rate down to 1Hz when the screen is static and up to 120Hz when needed. For example, when performing tasks involving primarily still images — such as checking emails or reading e-books and research papers — the panel operates at the lowest refresh rate of 1Hz. Conversely, it runs in high-refresh-rate mode at up to 120Hz when streaming content such as movies or sports as well as playing games with frequent screen changes.

Refresh rate refers to the number of times a screen is redrawn per second. A higher refresh rate reduces flickering, delivering smoother and clearer visuals. However, maintaining a high refresh rate on a static screen results in unnecessary power consumption due to continuous circuit operation.

By ushering in the unprecedented mass production of a laptop panel that flexibly adjusts the refresh rate based on on-screen activity, LG Display is able to offer a product that boasts greater power efficiency.

In order to achieve this world first, the company developed its own circuit algorithms and panel design technology, discovering new materials and applying the oxide with the lowest power leakage during low-refresh-rate mode to the display’s thin-film transistor (TFT).

The result is dramatically improved battery efficiency, including 48% more use on a single charge compared to existing solutions.

Considering mobility is a key purchasing factor for laptops, extending usage time with a high-efficiency battery is expected to significantly enhance consumer freedom and convenience. Furthermore, with the recent increase in AI computational tasks driving up power consumption, laptops incorporating Oxide 1Hz are anticipated to rise to even greater prominence.

LG Display will be supplying the Oxide 1Hz laptop panel to global PC manufacturer Dell for its flagship premium XPS lineup. Dell unveiled new XPS models featuring the panel at CES 2026 in January.

In addition, LG Display is preparing to begin mass production of a 1Hz OLED panel incorporating the same technology from 2027.

The company will continue to develop and apply energy-saving technologies such as Oxide 1Hz to advance its “Carbon Emission Reduction Project,” which aims to reduce carbon emissions during the product usage phase by up to 10%.

“We will deliver differentiated customer value through a 1-120Hz variable refresh rate that integrates world class technology,” said Jae-won Jang, Head of LG Display’s Medium Display Product Planning Division. “This unique value includes maximizing laptop battery efficiency for consumer convenience in the AI era.”

About LG Display

LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:
Joo Yeon Jennifer Ha, Team Leader, Communication Team
Email: hjy05@lgdisplay.com 

SHANGHAI, March 21, 2026 /PRNewswire/ — On March 21, the “Enlightening for Truth, Leading Global Change: Fudan Global MBA Program Launch Event” was held at the Zhengli Campus of School of Management at Fudan University (FDSM).

Fudan University and FDSM leadership attending the event included Kui Su, Director of the International Students Office of Fudan University; Professor Xiongwen Lu, Dean of FDSM; Professor Ming Zheng, Associate Dean of FDSM; Professor Cheng Zhang, Assistant Dean of FDSM; Professor Liyin Jin, Assistant Dean of FDSM; Professor Rong Huang, Assistant Dean of FDSM, and distinguished guests from all sectors. Neng Cao, Director of Fudan MBA Program, presided over the launch event.

Dean Xiongwen Lu delivered a keynote speech titled “From Following to Leading: China’s Answer to the Mission of Business Schools.”

He noted that for the past 40 years, the discourse and knowledge framework of global management education have been dominated by Western business schools. Looking ahead, Chinese management education should adopt a more open and confident global stance, transitioning from a “knowledge receiver” to a “knowledge constructor,” and from an “experience learner” to a “system exporter.” By utilizing Chinese business practices, the globalization experience of Chinese enterprises, and Chinese-style management innovation as core content, a new era of management education, one that is diverse, globally-oriented, and leading future business transformation, will begin.

Dean Lu emphasized that the Fudan Global MBA Program marks a milestone for Chinese management thinking, practice and education to participate in the new round of international educational competition and advance the globalization of China’s business education. Its core philosophy is to enable young global talents to gain in-depth insights into advanced industries, technologies and business practices in China and Asia, and draw experience and inspiration therefrom. Against the rapid development of the Internet, AI and the Internet of Things, the program will adopt a hybrid online-offline teaching model to expose students to top-tier curricula and research achievements. Through classroom learning, extracurricular practice and cross-cultural interaction, students will not only sharpen their professional skills but also cultivate a global vision and build comprehensive competence integrating theory and practice. More importantly, this will foster broader consensus among all parties and inject new momentum into the global economy. He sincerely invited all sectors of society to join this global cooperation journey and turn this vision into reality together.

Neng Cao, Director of Fudan MBA Program, introduced the detailed curriculum of the Fudan Global MBA Program in a presentation titled “Blossoming: The Global MBA for a New Era.”

He stated that the Fudan Global MBA Program aims to cultivate a new generation of global management talent with a deep understanding of Chinese culture, business wisdom, and global governance logic. This will promote the international dissemination of management thoughts with independent intellectual property rights, contributing “Chinese wisdom” to the development of global management science and elevating the voice and influence of Chinese management education on the global stage.

Centering on the “Fudan Global MBA” brand, the program integrates five value pillars: “China & World, Technology & Management, Culture & Business, Digital Intelligence & On-site Experience, and Academy & Industry.” Students will have a unique learning experience encompassing educational, experiential, career, cultural and resource value through four distinctive learning scenarios:

• Digital Knowledge Learning: Supported by digital technologies, the program integrates and develops core courses covering AI, Chinese industries, Chinese economy and Oriental management. It enables customized and modular learning, breaking the time and physical constraints of traditional classrooms to better suit global and part-time students across regions.
• Immersive Industry and Talent Connection: Implementing asynchronous collaboration, digital twin campuses, and VR/AR technology to foster immersive links between students, complemented by offline activities to strengthen intuitive understanding of Chinese business and culture.
• Action Learning for Real-world Problems: Leveraging 20 years of Fudan MBA Action Learning experience, the program focuses on three project types: “Globalizing Chinese Enterprises,” “Foreign Enterprises Entering the Chinese Market,” and “Business Challenges of Local Enterprises.” Students of this program will collaborate closely with Fudan MBA students to solve real business problems, sparking multi-perspective thinking and creating potential career opportunities. For student entrepreneurs, their projects will be included in a pre-admission communication and management process for Practical Achievements from the application stage, enabling precise resource matching to empower their entrepreneurial success.
• Lifelong Learning and Career Services: Graduates will enjoy lifelong digital updates for knowledge and career development services, including AI-matched recruitment information for Chinese enterprises overseas and foreign enterprises in China.

Neng Cao noted that the program is primarily designed for international students, featuring a part-time model, English-taught curriculum, and a 2-year duration.

The official Fudan Global MBA logo was also unveiled at the event by the attending leadership.

Since its re-establishment in 1985, FDSM has been rooted in Chinese business practices, engaged with cutting-edge global ideas, and implemented a proactive internationalization strategy of “going global and bringing in“. It has established extensive exchanges and partnerships with 116 renowned universities and research institutions across 32 countries and regions, including the United States, Italy, Norway, the United Kingdom, Australia, the Republic of Korea, and Hong Kong of China.

In 2009, FDSM received EQUIS accreditation from EFMD and successfully completed five-year re-accreditation in 2012, 2017 and 2023. Meanwhile, FDSM earned AACSB accreditation in 2010, followed by five-year re-accreditation in 2015 and 2020, and a six-year re-accreditation in 2025.

In the Financial Times Global EMBA 2025 Rankings, FDSM achieved its highest-ever result, with its programs ranking among the global top tier in overall and category-specific rankings. Four participating programs entered the global top 25, making FDSM the world’s only business school with four programs simultaneously ranked in the global top 25. Additionally, Fudan MBA Program remained in the global top 30 in the Financial Times Global MBA 2026 Rankings.

Official Links

• Fudan Global MBA Program:https://www.fdsm.fudan.edu.cn/globalmba/index.html
• Fudan University School of Management:https://www.fdsm.fudan.edu.cn/en/main.htm

HONG KONG, March 21, 2026 /PRNewswire/ — RyzoBee today announced that its Root Series is planned to launch on Kickstarter in Q2 2026 for the North American and European markets (timing subject to confirmation). In response to growing maker-community demand for more interactive 3D-printed creations, RyzoBee aims to provide 3D printing creators and makers with a modular electronics system centered around RootMaker—helping static prints gain lighting, motion, sensing, and networked interaction more quickly, and bringing projects closer to a showcase-ready, replicable finished state.

For many creators, the real hurdle isn’t modeling or printing—it’s what comes after: wiring, power, drivers, scattered resources, and a debugging process that’s hard to replicate reliably. Unlike traditional development boards that require manual wiring and piecemeal tutorials, RootMaker combines standardized connections and a consistent hardware form factor with ready-to-use firmware templates and a guided setup flow—making it easier to light up LEDs for the first time, drive motors, read sensors, or enable a web-based control panel in a more beginner-friendly, repeatable way.

As the central controller, RootMaker works with an expanding accessory ecosystem—including lighting, motors, sensors, and displays—and is paired with a web toolchain to streamline device management and template-based project workflows. Users can quickly flash firmware via the web toolchain, then complete configuration through the guided flow to get their project up and running. By standardizing previously fragmented debugging steps, the platform reduces repetitive troubleshooting and helps creators spend more time on design, interaction, and storytelling.

Designed for real-world integration, the Root Series also emphasizes “easy to mount, easy to use, easy to replicate” across both structure and expansion. It adopts a Technic-style mounting hole pattern to integrate smoothly with 3D-printed parts, kits, and modular frames, and plans to release an official open-source enclosure file library so users can start from a clean, printable baseline and customize from there. The platform also supports Arduino development: selected official projects will release Arduino code as open source, and Arduino IDE support will be provided (libraries and examples will be released alongside the Kickstarter launch).

RyzoBee will roll out community and content support across North America and Europe, including creator collaborations, quick-start materials, and open-source examples. To subscribe for Kickstarter launch notifications and get the latest updates, please visit: www.ryzobee.com

CONTACT: Ryzobee
pr@ryzobee.com

NEW YORK, March 21, 2026 /PRNewswire/ — GardePro, an innovator in outdoor smart monitoring technology, has launched the GardePro Link 1.0 Long-Range Wireless Trail Camera System (Hub and R3 Pro trail camera). Leveraging advanced 802.11ah long-range wireless technology, the system overcomes the range limitations of traditional Wi-Fi trail cameras. It is the world’s first trail camera capable of 3,000ft (1km) wireless transmission, real-time alerts, centralized multi-camera management, and remote HD photo uploads.

For years, farmers, ranchers and property managers have struggled with persistent limitations in traditional monitoring systems: Wi-Fi cameras have short transmission ranges, making it difficult to cover large areas or send remote trigger notifications, while cellular trail cameras require costly monthly data subscriptions. Users have urgently needed a cost-effective and easy-to-deploy long-range solution. The Link 1.0 was developed precisely to fill this void, providing a far more efficient way to monitor large properties.

“Cellular trail cameras deliver reliable long-range monitoring but come with prohibitively high monthly fees, putting this feature out of reach for many,” said Andy J., CEO of GardePro. “We’re making outdoor monitoring accessible at a far lower cost. Moving forward, we will continue upgrading our products with larger batteries and AI features to better meet users’ needs.”

Built on an integrated long-range wireless architecture combining a hub and camera, GardePro Link 1.0 offers several key advantages:

• Up to 3,000 ft / 1 km in clear line-of-sight conditions, and 1,600 ft / 485 m in typical use — nearly 20x the range of traditional Wi–Fi trail cameras.
• Real-time mobile push and email alerts when the camera is triggered. The mobile app enables remote adjustment of camera settings, device status checks, HD media browsing, and live streaming.
• A central hub that connects directly to a home Wi-Fi router, enabling stable remote access and management of up to 16 cameras for large-scale monitoring.
• Comes with a FREE 64GB SD card—ready to use right out of the box.

GardePro Link 1.0 is available for purchase now. For more information, visit https://gardepro.com/

Early adopters are already proving the system’s capabilities in the field. Leo, who manages a 50-acre wooded property, shared: “I stay connected even 2,550ft from my tree stand. These cameras are the best! They’ve captured deer, coyotes, skunks, raccoons, opossums, and cats—wildlife we’d never seen before.”

Outdoor enthusiast Benjamin C. praised Link 1.0’s reliability: “Great long-distance performance. 4K Clear daytime photos and night shots—ideal for my outdoor setup. The battery life is also outstanding. After 15 days of use, it still has 90% battery left.”

About GardePro

Since 2016, GardePro has adhered to its core philosophy of “Beyond Limits. Scout Smarter, Not Harder.” The company specializes in the R&D of high-performance trail cameras. GardePro products are widely used in hunting, farm management, security and wildlife observation, earning the trust of more than 8 million users worldwide.

Media Contacts
Company name: GardePro
Email address: market@gardepro.com

3,000+ companies now run trust on Sprinto, the platform replacing human-directed automation with governed agents that drive compliance to closure on their own

SAN FRANCISCO, March 21, 2026 /PRNewswire/ — Sprinto, the leading GRC and compliance automation platform, today launched its Autonomous Trust Platform, the first compliance infrastructure built around autonomous agents. This marks a shift from tools that assist compliance teams to systems that actively run compliance.

While compliance automation streamlined workflows and reduced manual effort, it still relies on humans to interpret changes, coordinate work, and drive issues to resolution. Autonomous Trust closes this gap.

Sprinto continuously monitors changes across systems, vendors, access, and AI usage, evaluates their impact in real time, and autonomously executes the work required to maintain compliance—from refreshing evidence and preparing audit artifacts to running vendor due diligence and resolving control gaps.

“Compliance automation still needs someone at the wheel. That was the right model for the last decade, but it doesn’t scale into the next one,” said Girish Redekar, Co-founder and CEO of Sprinto. “Autonomous Trust is the shift—humans for judgment, agents for everything else.”

The Autonomous Trust Platform is available now. Learn more at sprinto.com.

About Sprinto

Sprinto is the world’s first Autonomous Trust Platform, detecting change across your posture, determining what’s at risk, and acting across compliance, vendor risk, AI governance, and more, so your organization stays trustworthy without the operational chaos.

Sprinto is trusted by 3,000+ companies across 75 countries, including Emergent, CodeRabbit, Anaconda, and Whatfix. The platform supports 200+ global standards, including SOC 2, ISO 27001, GDPR, HIPAA, PCI-DSS, and ISO 42001, for AI governance across 300+ integrations.

Media Contact:
Payal Wadhwa
press@sprinto.com

• Treatment with ZEGFROVY^® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet
• WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-free, targeted therapy
• In addition to improvement in PFS, ZEGFROVY^® also showed superior results in all secondary endpoints, including cORR, DOR, DCR, compared to platinum-based chemo doublet
• ZEGFROVY^® was generally well tolerated with a safety profile consistent with previous studies  

SHANGHAI, March 21, 2026 /PRNewswire/ — Dizal (SSE:688192) today announced that its multinational Phase 3 WU-KONG28 study evaluating ZEGFROVY^® (sunvozertinib) monotherapy as first-line treatment in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint with positive topline results.

The findings suggest that ZEGFROVY monotherapy has the potential to become the first and only chemo free, oral agent to treat newly diagnosed NSCLC patients with EGFR exon20ins.

WU-KONG28 is a multinational, open-label, randomized confirmatory phase 3 study evaluating ZEGFROVY versus platinum-based chemotherapy as first-line treatment in advanced NSCLC patients with EGFR exon20ins. The study enrolled patients across 16 countries and regions in Asia, Europe, North America and South America. The primary endpoint is progression-free survival (PFS) assessed by blinded independent central review (BICR). Topline results demonstrated that ZEGFROVY significantly improved PFS compared to platinum-based doublet chemotherapy, with meaningful clinical benefit. Detailed data from the primary analysis will be submitted for presentation at an upcoming international scientific congress.

“Finding a drug targeting EGFR exon 20 insertion mutations is especially challenging due to their enormous heterogeneity. We have identified over 100 different subtypes of EGFR exon20ins clinically. Despite tremendous efforts, there is no success yet in finding an effective target drug that can spare patients from chemotherapies. WU-KONG28 study has the potential to change all that.” said Dr. Xiaolin Zhang, CEO of Dizal. “The success of this multinational pivotal study further validates ZEGFROVY’s potential as first-line therapy for patients with EGFR exon20ins NSCLC. We extend our sincere gratitude to the patients, their families, and the investigators worldwide for their dedication and contribution to this study. We look forward to sharing comprehensive data with the global scientific community.”

“The positive topline results from WU-KONG28 study represent an important advancement for treating patients with EGFR exon20ins NSCLC,” said Prof. Caicun Zhou, MD, PhD of Shanghai East Hospital and the principal investigator of the study. “ZEGFROVY is currently the only single-agent, small-molecule targeted therapy approved in both China and the United States for patients with EGFR exon 20 insertion NSCLC. In this Phase 3 trial, first-line treatment with ZEGFROVY significantly prolonged PFS compared to platinum-based doublet chemotherapy. These results suggest that ZEGFROVY may offer an effective and convenient treatment option for treatment-naïve patients with EGFR exon20ins NSCLC.”

ZEGFROVY was previously approved in both China and the U.S. for the treatment of relapsed or refractory NSCLC with EGFR exon20ins. In the first-line setting, ZEGFROVY has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration (FDA) and China Center for Drug Evaluation (CDE). Based on WU-KONG28 study results, Dizal plans to engage with regulatory authorities regarding potential new drug applications (NDAs).

About ZEGFROVY^®(sunvozertinib)

ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The approval in China is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1 Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication.

In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations, as well as HER2 exon20ins.

ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.

WU-KONG28, a multinational, randomized Phase 3 study conducted across 16 countries and regions evaluating ZEGFROVY as first-line treatment for patients with EGFR exon20ins NSCLC, met its primary endpoint.

Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies. Dizal has two approved: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

Contacts
Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com